Anti-Cancer Effect of Melatonin via Downregulation of Delta-like Ligand 4 in Estrogen-Responsive Breast Cancer Cells-Reference-Cited by-同舟云学术

Anti-Cancer Effect of Melatonin via Downregulation of Delta-like Ligand 4 in Estrogen-Responsive Breast Cancer Cells

Published:2020-12-29 Issue:4 Volume:15 Page:329-340
ISSN:1574-8928
Container-title:Recent Patents on Anti-Cancer Drug Discovery
language:en
Short-container-title:PRA

Author:

Rajabi Ali¹^ORCID,Saber Ali²,Pourmahdi Mahsa¹,Emami Ali¹,Ravanbakhsh Reyhaneh³,Khodavirdipour Amir¹,Khodaei Mehran¹,Akbarzadeh Molood⁴,Abdolahi Sepehr⁴,Hosseinpourfeizi Mohammad Ali¹,Safaralizadeh Reza¹^ORCID

Affiliation:

1. Department of Animal Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran

2. Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands

3. Department of Aquatic Biotechnology, Artemia and Aquaculture Research Institute, Urmia University, Urmia, Iran

4. Department of Biology, Faculty of Sciences, Azerbaijan Shahid Madani University, Tabriz, Iran

Abstract

Background: The Notch signaling pathway has a key role in angiogenesis and Delta-Like Ligand 4 (DLL4) is one of the main ligands of Notch involved in cell proliferation in sprouting vessels. Objective: In this study, we aimed to evaluate the expression of DLL4 in primary breast tumors and to examine the effect of melatonin on DLL4 expression in vitro. Methods: Eighty-five breast tumor and paired adjacent non-tumor tissue samples were collected. Apoptosis assay was performed on breast cancer cells to evaluate melatonin effects. Western blot and quantitative RT-PCR were used to measure DLL4 expression. Then, we investigated the effect of melatonin on the expression of DLL4 in four breast cancer cell lines at RNA and protein levels. We also performed Probabilistic Neural Network analysis to study genes closely associated with DLL4 expression. Results: Our results showed a significantly higher expression of DLL4 in tumor tissues as compared to non-tumor tissues (P = 0.027). Melatonin treatment substantially attenuated DLL4 expression in BT474 and MCF-7 cells, but not in SK-BR3 and MDA-MB-231 cells. Also, melatonin induced apoptosis in all four cell lines. Network analysis revealed a set of 15 genes that had close association and interaction with DLL4. DLL4 was overexpressed in breast cancer tissues as compared to the non-tumor tissues. Conclusion: It can be concluded that melatonin treatment attenuated DLL4 expression only in estrogen-responsive breast cancer cells and is able to induce apoptosis in breast cancer cells.

Publisher

Bentham Science Publishers Ltd.

Subject

Pharmacology (medical),Cancer Research,Drug Discovery,Oncology,General Medicine

Reference77 articles.

1. Bray F.; Ferlay J.; Soerjomataram I.; Siegel R.L.; Torre L.A.; Jemal A.; Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018,68(6),394-424

2. Pouladi N.; Abdolahi S.; Farajzadeh D.; Feizi M.A.H.P.; Association of the 17p13.1 region gene variants rs1042522 and rs2287499 with risk of breast cancer in Iranian-Azeri population. Meta Gene 2019,19,117-22

3. Reigosa A.; Hardisson D.; Sanzi F.; Caleiras E.; Saldivia F.; Fernández A.; Subclassification of the molecular types of breast cancer based on the expression of immunohistochemical markers and evolution. Invest Clin 2016,57(2),187-216

4. Mavaddat N.; Michailidou K.; Dennis J.; Lush M.; Fachal L.; Lee A.; Tyrer J.P.; Chen T.H.; Wang Q.; Bolla M.K.; Yang X.; Adank M.A.; Ahearn T.; Aittomäki K.; Allen J.; Andrulis I.L.; Anton-Culver H.; Antonenkova N.N.; Arndt V.; Aronson K.J.; Auer P.L.; Auvinen P.; Barrdahl M.; Beane Freeman L.E.; Beckmann M.W.; Behrens S.; Benitez J.; Bermisheva M.; Bernstein L.; Blomqvist C.; Bogdanova N.V.; Bojesen S.E.; Bonanni B.; Børresen-Dale A.L.; Brauch H.; Bremer M.; Brenner H.; Brentnall A.; Brock I.W.; Brooks-Wilson A.; Brucker S.Y.; Brüning T.; Burwinkel B.; Campa D.; Carter B.D.; Castelao J.E.; Chanock S.J.; Chlebowski R.; Christiansen H.; Clarke C.L.; Collée J.M.; Cordina-Duverger E.; Cornelissen S.; Couch F.J.; Cox A.; Cross S.S.; Czene K.; Daly M.B.; Devilee P.; Dörk T.; Dos-Santos-Silva I.; Dumont M.; Durcan L.; Dwek M.; Eccles D.M.; Ekici A.B.; Eliassen A.H.; Ellberg C.; Engel C.; Eriksson M.; Evans D.G.; Fasching P.A.; Figueroa J.; Fletcher O.; Flyger H.; Försti A.; Fritschi L.; Gabrielson M.; Gago-Dominguez M.; Gapstur S.M.; García-Sáenz J.A.; Gaudet M.M.; Georgoulias V.; Giles G.G.; Gilyazova I.R.; Glendon G.; Goldberg M.S.; Goldgar D.E.; González-Neira A.; Grenaker Alnæs G.I.; Grip M.; Gronwald J.; Grundy A.; Guénel P.; Haeberle L.; Hahnen E.; Haiman C.A.; Håkansson N.; Hamann U.; Hankinson S.E.; Harkness E.F.; Hart S.N.; He W.; Hein A.; Heyworth J.; Hillemanns P.; Hollestelle A.; Hooning M.J.; Hoover R.N.; Hopper J.L.; Howell A.; Huang G.; Humphreys K.; Hunter D.J.; Jakimovska M.; Jakubowska A.; Janni W.; John E.M.; Johnson N.; Jones M.E.; Jukkola-Vuorinen A.; Jung A.; Kaaks R.; Kaczmarek K.; Kataja V.; Keeman R.; Kerin M.J.; Khusnutdinova E.; Kiiski J.I.; Knight J.A.; Ko Y.D.; Kosma V.M.; Koutros S.; Kristensen V.N.; Krüger U.; Kühl T.; Lambrechts D.; Le Marchand L.; Lee E.; Lejbkowicz F.; Lilyquist J.; Lindblom A.; Lindström S.; Lissowska J.; Lo W.Y.; Loibl S.; Long J.; Lubiński J.; Lux M.P.; MacInnis R.J.; Maishman T.; Makalic E.; Maleva Kostovska I.; Mannermaa A.; Manoukian S.; Margolin S.; Martens J.W.M.; Martinez M.E.; Mavroudis D.; McLean C.; Meindl A.; Menon U.; Middha P.; Miller N.; Moreno F.; Mulligan A.M.; Mulot C.; Muñoz-Garzon V.M.; Neuhausen S.L.; Nevanlinna H.; Neven P.; Newman W.G.; Nielsen S.F.; Nordestgaard B.G.; Norman A.; Offit K.; Olson J.E.; Olsson H.; Orr N.; Pankratz V.S.; Park-Simon T.W.; Perez J.I.A.; Pérez-Barrios C.; Peterlongo P.; Peto J.; Pinchev M.; Plaseska-Karanfilska D.; Polley E.C.; Prentice R.; Presneau N.; Prokofyeva D.; Purrington K.; Pylkäs K.; Rack B.; Radice P.; Rau-Murthy R.; Rennert G.; Rennert H.S.; Rhenius V.; Robson M.; Romero A.; Ruddy K.J.; Ruebner M.; Saloustros E.; Sandler D.P.; Sawyer E.J.; Schmidt D.F.; Schmutzler R.K.; Schneeweiss A.; Schoemaker M.J.; Schumacher F.; Schürmann P.; Schwentner L.; Scott C.; Scott R.J.; Seynaeve C.; Shah M.; Sherman M.E.; Shrubsole M.J.; Shu X.O.; Slager S.; Smeets A.; Sohn C.; Soucy P.; Southey M.C.; Spinelli J.J.; Stegmaier C.; Stone J.; Swerdlow A.J.; Tamimi R.M.; Tapper W.J.; Taylor J.A.; Terry M.B.; Thöne K.; Tollenaar R.A.E.M.; Tomlinson I.; Truong T.; Tzardi M.; Ulmer H.U.; Untch M.; Vachon C.M.; van Veen E.M.; Vijai J.; Weinberg C.R.; Wendt C.; Whittemore A.S.; Wildiers H.; Willett W.; Winqvist R.; Wolk A.; Yang X.R.; Yannoukakos D.; Zhang Y.; Zheng W.; Ziogas A.; Dunning A.M.; Thompson D.J.; Chenevix-Trench G.; Chang-Claude J.; Schmidt M.K.; Hall P.; Milne R.L.; Pharoah P.D.P.; Antoniou A.C.; Chatterjee N.; Kraft P.; García-Closas M.; Simard J.; Easton D.F.; Polygenic risk scores for prediction of breast cancer and breast cancer subtypes. Am J Hum Genet ABCTB Investigators2019,104(1),21-34

5. Ghanbari M.; Hosseinpour-Feizi M.; Safaralizadeh R.; Aghazadeh A.; Montazeri V.; Study of KMT2B (MLL2) gene expression changes in patients with breast cancer. Breast Cancer Manag 2019,8(2),BMT24

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Apoptotic effect of melatonin on ER-positive breast cancer cell lines: ADGRL4 gene expression and promoter methylation;Naunyn-Schmiedeberg's Archives of Pharmacology;2024-08-23

2. Melatonin, circadian rhythms and breast cancer;Tumors of female reproductive system;2023-05-01

3. Progress on the role of traditional Chinese medicine in therapeutic angiogenesis of heart failure;Journal of Ethnopharmacology;2023-01

4. Expressions and Prognostic Values of Notch3 and DLL4 in Human Breast Cancer;Technology in Cancer Research & Treatment;2023-01

5. Development and Validation of Prognostic Nomograms Based on Lymph Node Ratio for Young Patients with Gastric Cancer: A SEER-Based Study;Technology in Cancer Research & Treatment;2023-01